生物大分子药物无创眼内递送研究进展  

Advances in Noninvasive Ocular Delivery of Biomacromolecules

作　　者：熊殷 樊星砚 王亦凡 魏刚[1,2,3] XIONG Yin;FAN Xingyan;WANG Yifan;WEI Gang(Ministry of Education Key Laboratory of Smart Drug Delivery,School of Pharmacy,Fudan University,Shanghai 201203,China;The Institutes of Integrative Medicine of Fudan University,Shanghai 200040,China;Shanghai Engineering Research Center of Immunotherapeutics,Shanghai 201203,China)

机构地区：[1]复旦大学药学院,教育部智能化递药重点实验室,上海201203 [2]复旦大学中西医结合研究院,上海200040 [3]上海市免疫治疗工程研究中心,上海201203

出　　处：《药学进展》2022年第4期244-254,共11页Progress in Pharmaceutical Sciences

基　　金：上海市科技创新行动计划资助项目(No.21S11905300,21ZR1407100);国家自然科学基金资助项目(No.81690263)。

摘　　要：生物大分子药物为许多眼科疾病患者带来了重见光明的希望,但由于眼部存在各种动态及静态吸收屏障,此类药物难以实现安全有效的眼内递送。临床上,生物大分子需通过眼内注射方式给药,而频繁的眼内注射伴随着诸多副作用,且患者顺应性差。构建理想的眼部药物递送系统,实现生物大分子的无创给药,尤其是将其递送至眼后段以治疗眼底疾病,始终是亟待满足的眼科需求。综述阻碍药物眼部吸收的各种生理屏障,以及近年来采用纳米递药系统、细胞穿膜肽及其他一些物理手段实现多肽蛋白类药物及基因药物眼内无创递送的研究进展,旨在为相关研究提供参考。Biomacromolecules hold the promise of restoring sight for many patients with eye diseases. Unfortunately, hampered by various dynamic and static ocular absorption barriers, it is hard to deliver biomacromolecules into the eye safely and effectively. In clinical practice,biomacromolecules need to be administered via intraocular injection. However, frequent intraocular injection is usually associated with various side-effects and poor patient compliance. Development of ideal ocular drug delivery systems to achieve noninvasive administration of biomacromolecules, especially delivery to the posterior segment of the eye for treatment of fundus oculi diseases, has always been the unmet need for ophthalmology. This article reviews the physiologic barriers that hinder ocular absorption of drugs and recent progress in noninvasive ocular delivery of peptides, proteins, and genes in virtue of nanotechnologies, cell-penetrating peptides, and other physical strategies, in attempt to provide some reference for related research.

关 键 词：眼部给药 生物大分子药物 吸收屏障 纳米递药系统 无创给药 细胞穿膜肽 

分 类 号：R944.9[医药卫生—药剂学]